We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits

By LabMedica International staff writers
Posted on 12 Mar 2026

Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. More...

A new study shows that different at-home gut health tests—and even repeated tests from the same provider—can produce conflicting bacterial abundance estimates and divergent health categorizations. The findings highlight persistent gaps in standardization.

In work from the National Institute of Standards and Technology, (NIST; Gaithersburg, MD, USA) investigators evaluated commercially available, direct-to-consumer gut microbiome testing kits. These services analyze an individual’s fecal sample to profile microbiome composition and, in many cases, convert those data into health assessments. The team focused on analytical performance across brands and replicate submissions to understand how methodological differences affect reported results.

The study assessed 21 test kits from seven anonymized providers, all analyzing the same combined fecal sample from a single donor. Reported relative abundances of specific taxa varied widely between companies, with the genus Clostridium—encompassing pathogens such as Clostridioides difficile—among the most variable findings. For context, the American Gut Project’s average abundance for Clostridium was just over 2.5%, yet one company reported approximately five times that level, while three others failed to detect the genus in one or more submissions. Within-brand consistency also diverged: three identical samples sent to the same provider yielded conflicting health categorizations, with one labeled “unhealthy” and two labeled “healthy.”

The authors attribute the discrepancies to nonstandardized sampling procedures, sample processing and analysis pipelines, and the distinct metrics individual companies apply to generate health scores. They propose that standardizing sampling protocols and testing methods could improve the accuracy and interpretability of direct-to-consumer microbiome testing. The findings are published in Communications Biology on February 26, 2026.

Related Links
National Institute of Standards and Technology


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.